Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33147041" target="_blank" >RIV/61989592:15110/13:33147041 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/13:#0002093 RIV/00843989:_____/13:E0103462 RIV/00216224:14110/13:00065643

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Popis výsledku v původním jazyce

The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight presence of dynamic equilibrium betwee co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activators changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival median was 30,3+-3,9 months for lowexpressed and 7,5+-5,6 months for high expressed group, p { 0,0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission median was 20,8+-3,6 months for low and 8,4+-2,7 months for high expressed group, p { 0,0001) as well as in whole studied cohort of MM patients (remission median was 20,8+-2,8 months for low and 9,8+-1,1 months for high expressed group, p { 0,0001). Overexpression of inhibitors can be explained as a compensato

Název v anglickém jazyce

Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Popis výsledku anglicky

The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight presence of dynamic equilibrium betwee co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activators changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival median was 30,3+-3,9 months for lowexpressed and 7,5+-5,6 months for high expressed group, p { 0,0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission median was 20,8+-3,6 months for low and 8,4+-2,7 months for high expressed group, p { 0,0001) as well as in whole studied cohort of MM patients (remission median was 20,8+-2,8 months for low and 9,8+-1,1 months for high expressed group, p { 0,0001). Overexpression of inhibitors can be explained as a compensato

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Genomics

ISSN

0888-7543

e-ISSN

—

Svazek periodika

102

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

243-249

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—